Tc‑99m Ser‑Asp‑Val‑Glu‑Cys‑Gly: A novel Tc‑99m labeled hexapeptide for molecular and non‑invasive tumor imaging

Kim,Dae‑Weung; Kim,Myoung Hyoun; Kim,Chang Guhn

doi:10.3892/mmr.2016.5811

Tc‑99m Ser‑Asp‑Val‑Glu‑Cys‑Gly: A novel Tc‑99m labeled hexapeptide for molecular and non‑invasive tumor imaging

Authors:
- Dae‑Weung Kim
- Myoung Hyoun Kim
- Chang Guhn Kim
View Affiliations

Affiliations: Department of Nuclear Medicine and Institute of Wonkwang Medical Science, Wonkwang University School of Medicine, Iksan, Jeollabuk‑do 570‑711, Republic of Korea
Published online on: October 6, 2016 https://doi.org/10.3892/mmr.2016.5811
Pages: 4887-4892

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In a ProteoChip‑based screening system and subsequent studies, serine‑aspartic acid‑valine (SDV) was demonstrated to specifically bind to integrin αvβ3. An SDV‑containing peptide could target the tumor vessel and it may be an effective replacement for molecular imaging of the tumor. In the present study, a hexapeptide, SDV‑glutamic acid‑cysteine‑glycine (ECG), was developed and evaluated its diagnostic performance as a tumor imaging agent in tumor‑bearing mice. The hexapeptide SDV‑ECG was synthesized using Fmoc solid‑phase peptide synthesis. Following radiolabeling procedures with technetium‑99m, the Tc‑99m SDV‑ECG complexes were prepared at high yields (>97%). The uptake of Tc‑99m SDV‑ECG within HT‑1080 tumor cells (integrin αvβ3‑positive) was confirmed by in vitro studies. γ‑camera imaging revealed substantial uptake of Tc‑99m SDV‑ECG in the HT‑1080 cell line tumor murine model. With the co‑injection of excess SDV, tumoral uptake was blocked. Furthermore, HT‑29 tumor cells (integrin αvβ3‑negative) and inflammatory lesions demonstrated minimal uptake of Tc‑99m SDV‑ECG. In the present study, Tc‑99m SDV‑ECG was developed as a novel Tc‑99m agent for tumor imaging. The current in vitro and in vivo studies demonstrated specific functions of Tc‑99m SDV‑ECG in tumor imaging.

View Figures

View References

1	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gladson CL and Cheresh DA: Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 88:1924–1932. 1991. View Article : Google Scholar : PubMed/NCBI
3	Veikkola T, Karkkainen M, Claesson-Welsh L and Alitalo K: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:203–212. 2000.PubMed/NCBI
4	Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R and Shapiro LH: CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 97:652–659. 2001. View Article : Google Scholar : PubMed/NCBI
5	Wang RE, Niu Y, Wu H, Amin MN and Cai J: Development of NGR peptide-based agents for tumor imaging. Am J Nucl Med Mol Imaging. 1:36–46. 2011.PubMed/NCBI
6	Kim DW, Kim WH, Kim MH and Kim CG: Novel Tc-99m labeled ELR-containing 6-mer peptides for tumor imaging in epidermoid carcinoma xenografts model: A pilot study. Ann Nucl Med. 27:892–897. 2013. View Article : Google Scholar : PubMed/NCBI
7	Lee Y, Kang DK, Chang SI, Han MH and Kang IC: High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip. J Biomol Screen. 9:687–694. 2004. View Article : Google Scholar : PubMed/NCBI
8	Choi Y, Kim E, Lee Y, Han MH and Kang IC: Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin. Proteomics. 10:72–80. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bang JY, Kim EY, Kang DK, Chang SI, Han MH, Baek KH and Kang IC: Pharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis. Mol Cell Proteomics. 10:M110.005264. 2011. View Article : Google Scholar : PubMed/NCBI
10	Dutta AK and Chacko A: Head mass in chronic pancreatitis: Inflammatory or malignant. World J Gastrointest Endosc. 7:258–264. 2015. View Article : Google Scholar : PubMed/NCBI
11	Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, Nishiwaki Y, Suzuki K and Nagai K: Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer. 47:235–242. 2005. View Article : Google Scholar : PubMed/NCBI
12	Kubota R, Kubota K, Yamada S, Tada M, Ido T and Tamahashi N: Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 35:104–112. 1994.PubMed/NCBI
13	Kim DW, Kim WH, Kim MH and Kim CG: Synthesis and evaluation of novel Tc-99m labeled NGR-containing hexapeptides as tumor imaging agents. J Labelled Comp Radiopharm. 58:30–35. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wu C, Wei J, Gao K and Wang Y: Dibenzothiazoles as novel amyloid-imaging agents. Bioorg Med Chem. 15:2789–2796. 2007. View Article : Google Scholar : PubMed/NCBI
15	Albelda SM and Buck CA: Integrins and other cell adhesion molecules. FASEB J. 4:2868–2880. 1990.PubMed/NCBI
16	Humphries MJ: Integrin structure. Biochem Soc Trans. 28:311–339. 2000. View Article : Google Scholar : PubMed/NCBI
17	Mousa SA: Anti-integrin as novel drug-discovery targets: Potential therapeutic and diagnostic implications. Curr Opin Chem Biol. 6:534–541. 2002. View Article : Google Scholar : PubMed/NCBI
18	Tucker GC: Inhibitors of integrins. Curr Opin Pharmacol. 2:394–402. 2002. View Article : Google Scholar : PubMed/NCBI
19	Carman CV: Overview: Imaging in the study of integrins. Methods Mol Biol. 757:159–189. 2012. View Article : Google Scholar : PubMed/NCBI
20	Gaertner FC, Kessler H, Wester HJ, Schwaiger M and Beer AJ: Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging 39 (Suppl 1). 126–138. 2012. View Article : Google Scholar
21	Shi P, Chen H, Cho MR and Stroscio MA: Peptide-directed binding of quantum dots to integrins in human fibroblast. IEEE Trans Nanobioscience. 5:15–19. 2006. View Article : Google Scholar : PubMed/NCBI
22	Liu S and Edwards DS: 99mTc-Labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 99:2235–2268. 1999. View Article : Google Scholar : PubMed/NCBI
23	van Waarde A, Jager PL, Ishiwata K, Dierckx RA and Elsinga PH: Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 47:150–154. 2006.PubMed/NCBI
24	Sugae S, Suzuki A, Takahashi N, Minamimoto R, Cheng C, Theeraladanon C, Endo I, Togo S, Inoue T and Shimada H: Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions. Ann Nucl Med. 22:65–72. 2008. View Article : Google Scholar : PubMed/NCBI
25	Fazaeli Y, Jalilian A, Amini M, Ardaneh K, Rahiminejad A, Bolourinovin F, Moradkhani S and Majdabadi A: Development of a (68)Ga-fluorinated porphyrin complex as a possible PET imaging agent. Nucl Med Mol Imaging. 46:20–26. 2012. View Article : Google Scholar : PubMed/NCBI
26	Shin KH, Park SA, Kim SY, Lee SJ, Oh SJ and Kim JS: Effect of animal condition and fluvoxamine on the result of [18F]N-3-Fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) Nortropane ([18F]FP-CIT) PET study in mice. Nucl Med Mol Imaging. 46:27–33. 2012. View Article : Google Scholar : PubMed/NCBI
27	Berger M, Gould MK and Barnett PG: The cost of positron emission tomography in six United States veterans affairs hospitals and two academic medical centers. AJR Am J Roentgenol. 181:359–365. 2003. View Article : Google Scholar : PubMed/NCBI
28	Matthews KM, Bowyer TW, Saey PR and Payne RF: The workshop on signatures of medical and industrial isotope production-WOSMIP; Strassoldo, Italy, 1–3 July 2009. J Environ Radioact. 110:1–6. 2012. View Article : Google Scholar : PubMed/NCBI